000117961 001__ 117961
000117961 005__ 20230519145602.0
000117961 0247_ $$2doi$$a10.31083/j.ejgo4204099
000117961 0248_ $$2sideral$$a128047
000117961 037__ $$aART-2021-128047
000117961 041__ $$aeng
000117961 100__ $$aBaquedano Mainar, Laura$$uUniversidad de Zaragoza
000117961 245__ $$aClinical and demographic factors in endometrial and ovary carcinoma: Synchronous carcinoma vs stage IIIA endometrial carcinoma
000117961 260__ $$c2021
000117961 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117961 5203_ $$aObjective: To compare pre-surgical demographic and clinical factors and preoperative serum tumor marker values of patients with endometrial and ovarian synchronous carcinoma with those diagnosed with endometrial carcinoma with metastatic ovarian involvement (FIGO stage IIIA). Methods: A retrospective observational study including patients with endometrial and ovarian malignant tumors that were treated at Miguel Servet University Hospital, Zaragoza, Spain, since January 2000 to June 2020. All pathologic specimens were reviewed by two pathologists specialized in gynecological oncology. Results: Overall, 51 patients were included. 24 cases of them, were endometrial and ovarian synchronous primary carcinomas and the remaining 27 cases were endometrial tumors with adnexa. Parity, personal and family oncological history, arterial hypertension, diabetes, dyslipidemia, obesity and the prior use of hormone replacement therapy did not show significant differences between both groups. Age (p = 0.002), menopausal status (p = 0.029), abnormal uterine bleeding (p = 0.001), Ca 12.5 preoperative serum level (p = 0.038) and Ca 19.9 preoperative serum level (0.028) were factors with significant differences between both groups. In multivariate analysis, only abnormal uterine bleeding and Ca 19.9 values were independents factors. Conclusions: The presence of abnormal uterine bleeding and Ca 19.9 preoperative serum level could guide the clinician in the preoperative differential diagnosis between endometrial cancer with ovarian involvement and endometrial and ovarian synchronous carcinoma. © 2021 The Author(s).
000117961 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117961 590__ $$a0.255$$b2021
000117961 592__ $$a0.0$$b2021
000117961 591__ $$aONCOLOGY$$b243 / 245 = 0.992$$c2021$$dQ4$$eT3
000117961 593__ $$aOncology$$c2021
000117961 591__ $$aOBSTETRICS & GYNECOLOGY$$b83 / 85 = 0.976$$c2021$$dQ4$$eT3
000117961 593__ $$aObstetrics and Gynecology$$c2021
000117961 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117961 700__ $$aNavarro Sierra, Javier
000117961 700__ $$0(orcid)0000-0001-8957-2352$$aAlvárez Sarrado, Leticia
000117961 700__ $$aJosé Gutiérrez, Yasmina
000117961 700__ $$aLamarca Ballestero, Marta
000117961 700__ $$aRubio Cuesta, Patricia
000117961 700__ $$aRuiz Peña, Ana C.
000117961 700__ $$aEspiau Romera, Andrea$$uUniversidad de Zaragoza
000117961 7102_ $$11013$$2645$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Obstetricia y Ginecología
000117961 773__ $$g42, 4 (2021), 643-648$$pEur. j. gynaecol. oncol.$$tEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY$$x0392-2936
000117961 8564_ $$s116183$$uhttps://zaguan.unizar.es/record/117961/files/texto_completo.pdf$$yVersión publicada
000117961 8564_ $$s2929099$$uhttps://zaguan.unizar.es/record/117961/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117961 909CO $$ooai:zaguan.unizar.es:117961$$particulos$$pdriver
000117961 951__ $$a2023-05-18-16:00:48
000117961 980__ $$aARTICLE